Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis

Archives of Medical Science

Volumn 8, Issue 5, 2012, Pages 767-775

  Kawalec, Paweł ^a   Paszulewicz, Anna ^a   Holko, Przemysław ^a   Pilc, Andrzej ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

APC 8015; Prostate cancer vaccine; Provenge; Sipuleucel T

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

ANEMIA; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; META ANALYSIS; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84869758444     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.31610     Document Type: Review

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Reports from the National Cancer Database according to The Oncology Centre data http://www.onkologia.org.pl/pl/p/7/.
3. Kozłowska E, Szewczyk MT, Banaszkiewicz Z, Jawień A, Cierzniakowska K, Jarmocik P. Knowledge of symptoms and diagnostic possibilities of cancer diseases. Arch Med Sci 2011; 7: 304-9.
4. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate- term results. J Urol 1998; 160: 2428-34.
5. Eastham JA, Scardino PT. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Comprehensive textbook of genitourinary oncology. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds). 2nd ed. Lipincott Williams & Wilkins, Philadelphia 1999.
6. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-6.
7. Clark PE, Levin HS, Kupelian PA, Reddy C, Zippe CD, Klein EA. Intermediate-term outcome with radical prostatectomy for localized prostate cancer: the Cleveland Clinic experience. Prostate J 2001; 3: 118-25.
8. Kantoff PW, Carrol PR, D'Amico AV, eds. Prostate cancer: principles and practice. Lippincott Williams & Wilkins, Philadelphia 2002.
9. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44.
10. Sonpavde G, Di Lorenzo G, Higano CS, et al. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61: 639-47.
11. Taxotere® (docetaxel): EPAR - product information http://www.ema.europa.eu/docs/pl-PL/document-library/EPAR---Product-Information/ human/000073/WC500035264.pdf
12. Zaborowska M, Szmit S, Szczylik C. Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option? Arch Med Sci 2012; 8: 528-32.
13. Patel PH, Kockler DR. Sipuleucel-T. A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008; 42: 91-8.
14. http://www.fda.gov/downloads/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/UCM213114.pdf
15. Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration and John Wiley 2008.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996; 17: 1-12.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
19. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
20. Microsoft Office Excel®2007 [Computer program], Microsoft® Corporation.
21. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory. J Clin Oncol 2006; 24: 3089-94.
22. Small EJ, Rini B, Higano C, et al. A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa). Proc Am Soc Clin Oncol 2003; 22: 382, Abstract 1534.
23. Schellhammer PF, Small EJ, Higano CS, et al. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: a phase III randomized, double-blind, placebo controlled trial. Proc Am Soc Clin Oncol 2002; 21: 183a, Abstract 731.
24. Lee D. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015). Clin Prostate Cancer 2003; 2: 81-3.
25. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9.
26. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
27. George DJ, Vogelzang N, Schellhammer PF, et al. Survival results of the IMPACT trial of sipuleucel-T for advanced prostate cancer. Ann Oncol 2010; 21 (Suppl 8): 272.
28. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2010. Oral Abstract Session A: Prostate Cancer.
29. Nabhan C, Gomella LG, DeVries T, et al. An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study. J Clin Oncol 2012; 30 (Suppl 5): Abstract 144.
30. George DJ, Nabhan LG, Gomella JB, et al. Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies. J Clin Oncol 2011; 29 (Suppl 7): Abstract 139.
31. Gomella JB, Nabhan LG, Whitmore JB, et al. Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies. J Clin Oncol 2011; 29 (Suppl): Abstract 4534.
32. Small EJ, Higano CS, Kantoff PW, et al. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC): results from 3 randomized phase III trials. Eur J Cancer 2011; 47 (Suppl 1): 484.
33. Draft Guidance for Industry: clinical considerations for therapeutic cancer vaccines. Washington, DC: Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2009. (Accessed February 10, 2012, http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm182443.htm.
34. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin- A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double- blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-23.
35. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105.
36. James ND, Borre M, Zonnenberg BA, et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases. EJC Supplements 2007; 5: 3.
37. Kantoff PW, Glode LM, Tannenbaum SI, Billhartz DL, Pitman WG, Schuetz TJ. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone-refractory prostate cancer. J Clin Oncol ASCO Annu Mtg Proc 2006; 24: 2501.
38. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.
39. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17: 4558-67.
40. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903.
41. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11: 805-12.
42. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010; 15: 969-75.